Functional Selectivity at GPCRs: New Opportunities in Psychiatric Drug Discovery
- 9 December 2013
- journal article
- editorial
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 39 (1) , 248-249
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Structural Features for Functional Selectivity at Serotonin ReceptorsScience, 2013
- Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium actionProceedings of the National Academy of Sciences, 2012
- Signalling bias in new drug discovery: detection, quantification and therapeutic impactNature Reviews Drug Discovery, 2012
- Selective p38α MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and AddictionNeuron, 2011
- Serotonin, But NotN-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling ComplexIn VivoThe Journal of Neuroscience, 2010
- Beyond Desensitization: Physiological Relevance of Arrestin-Dependent SignalingPharmacological Reviews, 2010
- Kinase cascades and ligand-directed signaling at the kappa opioid receptorPsychopharmacology, 2010